Insomnia

A therapeutic review for pharmacists

Pamela Foral, Naresh Dewan, Mark A. Malesker

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

OBJECTIVE: To review the literature for the management of insomnia. DATA SOURCE: MEDLINE/PUBMED searches (January 1950-June 2010) were conducted to identify pertinent English-language studies. STUDY SELECTION AND DATA EXTRACTION: All studies evaluating aspects of the treatment of insomnia. DATA SYNTHESIS: Insomnia is a major public health problem requiring effective diagnosis and treatment. Treatment options include cognitive behavioral therapy as well as pharmacologic therapy. Benzodiazepine receptor-agonist modulators are considered first-line therapy in the treatment of chronic insomnia. A nonbenzodiazepine receptor-modulator option to improve sleep latency is ramelteon. Low-dose sedative antidepressants, such as quetiapine or olanzapine, may be used in the treatment of comorbid insomnia. Over-the-counter and herbal agents are not recommended. CONCLUSION: Numerous medications being used in the management of insomnia have side effects that can limit their use and have a potential for drug interactions. Furthermore, some medications used in the treatment of insomnia do not have clinical trial data to support their use. Future studies are warranted to define second- and third-line agents in the management of insomnia.

Original languageEnglish
Pages (from-to)332-341
Number of pages10
JournalConsultant Pharmacist
Volume26
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Sleep Initiation and Maintenance Disorders
Pharmacists
Therapeutics
olanzapine
Cognitive Therapy
GABA-A Receptors
Hypnotics and Sedatives
Drug Interactions
MEDLINE
Antidepressive Agents
Sleep
Language
Public Health
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Insomnia : A therapeutic review for pharmacists. / Foral, Pamela; Dewan, Naresh; Malesker, Mark A.

In: Consultant Pharmacist, Vol. 26, No. 5, 05.2011, p. 332-341.

Research output: Contribution to journalReview article

Foral, Pamela ; Dewan, Naresh ; Malesker, Mark A. / Insomnia : A therapeutic review for pharmacists. In: Consultant Pharmacist. 2011 ; Vol. 26, No. 5. pp. 332-341.
@article{05802543452e48b2b5b3d0eccceebfc6,
title = "Insomnia: A therapeutic review for pharmacists",
abstract = "OBJECTIVE: To review the literature for the management of insomnia. DATA SOURCE: MEDLINE/PUBMED searches (January 1950-June 2010) were conducted to identify pertinent English-language studies. STUDY SELECTION AND DATA EXTRACTION: All studies evaluating aspects of the treatment of insomnia. DATA SYNTHESIS: Insomnia is a major public health problem requiring effective diagnosis and treatment. Treatment options include cognitive behavioral therapy as well as pharmacologic therapy. Benzodiazepine receptor-agonist modulators are considered first-line therapy in the treatment of chronic insomnia. A nonbenzodiazepine receptor-modulator option to improve sleep latency is ramelteon. Low-dose sedative antidepressants, such as quetiapine or olanzapine, may be used in the treatment of comorbid insomnia. Over-the-counter and herbal agents are not recommended. CONCLUSION: Numerous medications being used in the management of insomnia have side effects that can limit their use and have a potential for drug interactions. Furthermore, some medications used in the treatment of insomnia do not have clinical trial data to support their use. Future studies are warranted to define second- and third-line agents in the management of insomnia.",
author = "Pamela Foral and Naresh Dewan and Malesker, {Mark A.}",
year = "2011",
month = "5",
doi = "10.4140/TCP.n.2011.332",
language = "English",
volume = "26",
pages = "332--341",
journal = "The Senior care pharmacist",
issn = "2639-9636",
publisher = "American Society of Consultant Pharmacists",
number = "5",

}

TY - JOUR

T1 - Insomnia

T2 - A therapeutic review for pharmacists

AU - Foral, Pamela

AU - Dewan, Naresh

AU - Malesker, Mark A.

PY - 2011/5

Y1 - 2011/5

N2 - OBJECTIVE: To review the literature for the management of insomnia. DATA SOURCE: MEDLINE/PUBMED searches (January 1950-June 2010) were conducted to identify pertinent English-language studies. STUDY SELECTION AND DATA EXTRACTION: All studies evaluating aspects of the treatment of insomnia. DATA SYNTHESIS: Insomnia is a major public health problem requiring effective diagnosis and treatment. Treatment options include cognitive behavioral therapy as well as pharmacologic therapy. Benzodiazepine receptor-agonist modulators are considered first-line therapy in the treatment of chronic insomnia. A nonbenzodiazepine receptor-modulator option to improve sleep latency is ramelteon. Low-dose sedative antidepressants, such as quetiapine or olanzapine, may be used in the treatment of comorbid insomnia. Over-the-counter and herbal agents are not recommended. CONCLUSION: Numerous medications being used in the management of insomnia have side effects that can limit their use and have a potential for drug interactions. Furthermore, some medications used in the treatment of insomnia do not have clinical trial data to support their use. Future studies are warranted to define second- and third-line agents in the management of insomnia.

AB - OBJECTIVE: To review the literature for the management of insomnia. DATA SOURCE: MEDLINE/PUBMED searches (January 1950-June 2010) were conducted to identify pertinent English-language studies. STUDY SELECTION AND DATA EXTRACTION: All studies evaluating aspects of the treatment of insomnia. DATA SYNTHESIS: Insomnia is a major public health problem requiring effective diagnosis and treatment. Treatment options include cognitive behavioral therapy as well as pharmacologic therapy. Benzodiazepine receptor-agonist modulators are considered first-line therapy in the treatment of chronic insomnia. A nonbenzodiazepine receptor-modulator option to improve sleep latency is ramelteon. Low-dose sedative antidepressants, such as quetiapine or olanzapine, may be used in the treatment of comorbid insomnia. Over-the-counter and herbal agents are not recommended. CONCLUSION: Numerous medications being used in the management of insomnia have side effects that can limit their use and have a potential for drug interactions. Furthermore, some medications used in the treatment of insomnia do not have clinical trial data to support their use. Future studies are warranted to define second- and third-line agents in the management of insomnia.

UR - http://www.scopus.com/inward/record.url?scp=80051556411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051556411&partnerID=8YFLogxK

U2 - 10.4140/TCP.n.2011.332

DO - 10.4140/TCP.n.2011.332

M3 - Review article

VL - 26

SP - 332

EP - 341

JO - The Senior care pharmacist

JF - The Senior care pharmacist

SN - 2639-9636

IS - 5

ER -